Cancer Research includes companies working on scientific research aimed at understanding the causes, prevention, diagnosis, treatment, and potential cures for cancer. It includes many disciplines, from biology and genetics, to clinical trials and drug development, with the ultimate goal of improving cancer care and outcomes. Cancer research companies are developing life-saving treatments and diagnostics for a growing market in high demand. These companies constantly innovate, have a global reach, and form important strategic partnerships, which makes them appealing to investors looking for profits and supporting health progress.
MRNA Is Promising A Breakthrough In Fighting Cancer
When it comes to cancer, there's innovation both on the diagnostics and the treatment front thanks to messenger RNA, or mRNA, a genetic material we all got acquainted with during the COVID-19 era as i
Benzinga12minutes ago
Jumo Health to Lead a Roundtable Discussion on Authenticity and the Patient Voice at the Annual Health Equity in Clinical Trials Congress
NEW HAVEN, Conn., April 29, 2024 /PRNewswire/ -- Jumo Health—a global provider of age-appropriate, culturally relevant medical education—today announced that Kevin Aniskovich, the Company's President
PR Newswire22minutes ago
These Pharmaceutical Firms Are on Sale: AbbVie, Pfizer, and Gilead
Baystreet.ca22minutes ago
Earnings Call Summary | Bristol-Myers Squibb(BMY.US) Q1 2024 Earnings Conference
The following is a summary of the Bristol-Myers Squibb Company (BMY) Q1 2024 Earnings Call Transcript:Financial Performance:Bristol-Myers Squibb Company reported a strong Q1 in 2024 with significant g
moomoo AI36minutes ago · Conference Call
Monday's Top Stocks: Alphabet, Nvidia, Pfizer, and More
Baystreet.ca09:08 ET
Repertoire collaborates with BMY.US to develop 3 autoimmune vaccines
The Zhitong Finance App learned that on April 29, Repertoire Immune Medicines, a biotechnology company that pioneered the discovery and development of programmable T-cell-targeted immune drugs, announced that it had reached a cooperation agreement with BMY.US (BMY.US) to develop “tolerable vaccines” for 3 types of autoimmune diseases. The collaboration aims to develop effective, selective, and long-lasting treatments for patients with autoimmune diseases by resetting the immune system. Under the terms of the agreement, Repertoire will receive an advance payment of 65 million US dollars, as well as an advance payment of up to 1.8 billion US dollars,
Zhitong Finance09:04 ET
Express News | Merck: Immune Responses Elicited by V116 Were Superior for Nine Serotypes Included in V116 but Not Ppsv23, as Measured by Opa Gmt Ratios at Day 30
Reuters09:00 ET
Express News | Merck & Co Inc: V116 Elicited Immune Responses That Were Noninferior Compared to Ppsv23 for 12 Serotypes (or Strains) Common to Both Vaccines
Reuters09:00 ET
Express News | Merck & Co Inc: V116 Had a Safety Profile Comparable to Ppsv23
Reuters09:00 ET
Express News | Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
Reuters09:00 ET
Impacted by reports of drug safety issues, Morphosys (MOR.US) says the Novartis Pharmaceuticals (NVS.US) acquisition will continue as planned
The Zhitong Finance App learned that on Monday, the stock price of German biotech company Morphosys (MOR.US) fell due to a news report about its drugs or safety risks, but Morphosys said that Novartis Pharmaceuticals (NVS.US) is still expected to complete its acquisition in the first half of this year. Prior to Morphosys' statement, the professional website StatNews quoted two people familiar with the matter as reporting that the company is developing an experimental drug pelabresib to treat myelofibrosis (a rare type of blood cancer affecting bone marrow)
Zhitong Finance08:21 ET
Oppenheimer Remains a Buy on Biogen (BIIB)
TipRanks07:58 ET
Pfizer (PFE) Gets a Buy From Truist Financial
TipRanks07:53 ET
Express News | FDA Approves Labcorp's NAbCyte Anti-AAVRh74var HB-FE, Companion Diagnostic To Determine Patient Eligibility For Treatment With Beqvez (Fidanacogene Elaparvovec-dzkt), Pfizer's Recently FDA-Approved Hemophilia B Gene Therapy
Benzinga07:04 ET
Express News | Labcorp Receives FDA Approval for First Companion Diagnostic for Use With Pfizer's Newly Approved Gene Therapy to Treat Patients With Hemophilia B
Reuters07:00 ET
Bristol Myers, Repertoire to Develop Tolerizing Vaccines in Multi-year Pact
Seeking Alpha06:56 ET
Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Keeps Hold Rating
Bristol-Myers Squibb (BMY) has an average rating of hold and a price target range of $37 to $75, according to analysts polled by Capital IQ. Price: 45.05, Change: +0.20, Percent Change: +0.45
MT Newswires06:45 ET
Express News | Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at Asco 2024 Annual Meeting
Reuters06:45 ET
Earnings Volatility | Options Market Sees Big Move in Apple, AMD, and Amazon Shares
Stock prices may see larger-than-normal moves during earnings season, making it a potentially attractive time for options traders. For investors looking to trade against these moves, you should always keep track of how the options might shift after their earnings.
Options Newsman06:38 ET
Express News | Gilead : Barclays Cuts Target Price to $76 From $80
Reuters06:28 ET